The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Duration of androgen deprivation therapy for high-risk prostate cancer: Application of randomized trial data in a tertiary referral cancer center.
 
Vinayak Muralidhar
No Relationships to Disclose
 
Meredith M. Regan
Research Funding - AstraZeneca (Inst); Celgene (Inst); Ferring (Inst); Ipsen (Inst); Merck (Inst); Novartis (Inst); OncoGenex (Inst); Pfizer (Inst); Veridex (Inst)
 
Lillian Werner
No Relationships to Disclose
 
Mari Nakabayashi
No Relationships to Disclose
 
Carolyn Evan
No Relationships to Disclose
 
Joaquim Bellmunt
Consulting or Advisory Role - Astellas Pharma; Genentech; Merck; Pfizer; Pierre Fabre
Research Funding - Millennium (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Pfizer
 
Toni K. Choueiri
Honoraria - NCCN; UpToDate
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb (Inst); GlaxoSmithKline; Merck; Novartis; Pfizer
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst)
 
Aymen Elfiky
Consulting or Advisory Role - McKinsey & Company
 
Lauren Christine Harshman
Consulting or Advisory Role - Bristol-Myers Squibb; Dendreon; Genentech; Medivation/Astellas; NCCN; Pfizer; PlatformQ Health
Research Funding - Bayer; Medivation/Astellas
 
Rana R. McKay
Research Funding - Bayer (Inst); Pfizer (Inst)
 
Mark Pomerantz
No Relationships to Disclose
 
Christopher Sweeney
Stock and Other Ownership Interests - BIND Biosciences; Leuchemix
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; BIND Biosciences; Genentech/Roche; Janssen Biotech; Sanofi
Research Funding - Astellas Pharma (Inst); Exelixis (Inst); Janssen Biotech (Inst)
Patents, Royalties, Other Intellectual Property - Leuchemix, Parthenolide, Dimethylaminoparthenolide. Exelixis: Abiraterone plus cabozantinib combination
 
Mary-Ellen Taplin
Honoraria - Bayer; Dendreon; Janssen-Ortho; Medivation; Tokai Pharmaceuticals
Consulting or Advisory Role - Bayer; Best Doctors, Inc; Dendreon; Gerson Lehrman Group; Guidepoint Global; Janssen-Ortho; Medivation; Sanofi; Tokai Pharmaceuticals; UpToDate
Research Funding - Bayer; Genentech; Janssen-Ortho; Medivation
Travel, Accommodations, Expenses - Dendreon; Janssen Oncology; Medivation; Tokai Pharmaceuticals
 
Philip W. Kantoff
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; BIND Biosciences; Blend Therapeutics; Metamark Genetics
Consulting or Advisory Role - Amgen; Aragon Pharmaceuticals; Archimedes; Astellas Pharma; Auven Therapeutics; Bavarian Nordic; Bayer; Bellicum Pharmaceuticals; BIND Biosciences; Blend Therapeutics; Celgene; Dendreon; Endocyte; Exelixis; Genomic Health; GTx; Janssen; Medivation; Merck; Metamark Genetics; Millennium; MorphoSys; MTG Therapeutics; OncoCellMDX; Oncogenex; Pfizer; Progenics; Roche; Sanofi; Sotio; Teva; Tokai Pharmaceuticals
Research Funding - Amgen (Inst); Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); Bayer (Inst); Dendreon (Inst); Exelixis (Inst); Janssen Oncology (Inst); Medivation (Inst); Oncogenex (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bavarian Nordic; BIND Biosciences; Janssen; Millennium; Progenics; Sanofi
 
Paul L. Nguyen
Consulting or Advisory Role - Abbott Diagnostics (I); Ferring; GenomeDx; Medivation
Patents, Royalties, Other Intellectual Property - Wife has a patent on volatile diagnostics of infections (I)